DAWN Q4 2025 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M+83.9% YoY

Gross Profit

$48M88.7% margin

Operating Income

-$27M-51.1% margin

Net Income

-$21M-39.6% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+35.0%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$18M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$508M

Total Liabilities

$67M

Stockholders' Equity

$441M

Cash & Equivalents

$197M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$29M	+83.9%
Gross Profit	$48M	$26M	+81.6%
Operating Income	-$27M	-$65M	+58.0%
Net Income	-$21M	-$66M	+67.6%

Revenue Segments

Product

$53M98%

License

$884,0002%